Agricultural Biotechnology Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Agricultural Biotechnology market is a compilation of the market of Agricultural Biotechnology broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Agricultural Biotechnology industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Agricultural Biotechnology industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Agricultural Biotechnology Market report @ https://hongchunresearch.com/request-a-sample/64512

The following manufacturers are covered:SyngentaDuPontMonsantoADAMA Agricultural SolutionsBASFBayer CropScienceCertis USADow AgroSciencesMycogen SeedPerformance PlantsKWS SAATEvogeneRubiconVilmorinGlobal Bio-chem Technology

Access this report Agricultural Biotechnology Market @ https://hongchunresearch.com/report/worldwide-agricultural-biotechnology-market-2019-64512

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeMolecular MarkersVaccinesGenetic EngineeringTissue CultureMolecular DiagnosticsOther

Segment by ApplicationTransgenic Crops/SeedsBiopesticidesOther

For a global outreach, the Agricultural Biotechnology study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Agricultural Biotechnology Market @ https://hongchunresearch.com/check-discount/64512

Major Point of TOC:

Chapter One: Agricultural Biotechnology Market Overview

Chapter Two: Global Agricultural Biotechnology Market Competition by Manufacturers

Chapter Three: Global Agricultural Biotechnology Production Market Share by Regions

Chapter Four: Global Agricultural Biotechnology Consumption by Regions

Chapter Five: Global Agricultural Biotechnology Production, Revenue, Price Trend by Type

Chapter Six: Global Agricultural Biotechnology Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Agricultural Biotechnology Business

Chapter Eight: Agricultural Biotechnology Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Agricultural Biotechnology Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

The rest is here:
Impact Of Covid-19 on Agricultural Biotechnology Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Crypto Daily

TEHRAN Iran is playing the leading role in the region in the fields of fintech, ICT, stem cell, aerospace, and is unrivaled in artificial intelligence, Sourena Sattari, the vice president for science and technology, told the Tehran Times in an exclusive interview on Saturday.

He went on to say that in terms of biotechnology Iran is at the forefront by producing 24 biomedicines.

U.S. sanctions caused exports of knowledge-based companies to decline three years ago, however, it has returned to growth and is projected to reach the pre-sanctions level of more than $1 billion by the end of the current [Iranian calendar] year (March 20, 2021), he emphasized.

Production of COVID-19 test kits

Referring to the domestic production of COVID-19 test kits, Sattari highlighted that some of the knowledge-based companies reached a production capacity of more than 200-300 thousand diagnostic kits per day.

Currently, 6 companies have been approved to produce these kits, and a newly-approved company recently was tasked with the production of 1.5 million kits, he added.

Pointing out that multiplying the production of COVID-19 equipment led to a significant foreign currency saving for the country, he said it also helped us cope with problems and not to run out of equipment because no matter how much money we gave, no country had the equipment to sell.

In such a condition, we were not only able to quickly adapt and produce all needed equipment, but to produce some manufacturing machines, and considerably reduce imports.

He went on to emphasize that the country not only can fully meet its need for diagnostic kits, but there is a great export potential.

Export-oriented firms supported

We have so far sent medical and self-protective equipment to many countries for fighting COVID-19, Sattari said, adding, there are 30 centers in other countries to follow up on export confirmation, as some knowledge-based products take up to 10 years to receive export approval.

So far, over six medicines have received export confirmation in Russia and are being exported, he noted, stating that, due to the complexities of exporting knowledge-based products, we have prepared plans to support export-oriented startups.

To support exporters, we pay up to 90 percent of the cost of obtaining standards and patent registration, the cost of registering products in foreign countries, as well as provision of significant financial assistance for participation in foreign exhibitions, in addition to granting them low-interest loans, and most importantly, we analyze export opportunities for the companies and help them find the proper export market. In other words, we provide them with comprehensive information, he explained.

Students abroad highly supported to return

Unfortunately, there is not a large number of Iranian students abroad, only a total of 50,000 students, which is over 1 percent of our total student population, and this number is not satisfactory, but the quality of students abroad is good and that is why we have been working hard on policies to bring them back since the past four years, he stated.

Sattari went on to note that so far, more than 1,800 students have returned from the top 100 universities in the world, nearly 400 of whom have been graduated from the worlds top 20 universities. Our supports are in the form of a different package of features, and we provide all the communications for them before they return.

The return trend has intensified after the pandemic, previously 1.5 people returned to the country per day, but now it has reached more than 2 people, he highlighted.

There is another issue, for example, some students decide to return for a short period and hold various workshops and courses in universities and research centers, for whom we also provide financial support, Sattari noted.

Record sale of $28.5 billion

"Knowledge-based companies promoted a new culture in the country that does not have physical assets but generates millions of dollars through producing knowledge.

Fortunately, last year, companies achieved a record sale of 1.2 quadrillion rials (nearly $28.5 billion at the official rate of 42,000 rials), which is expected to increase by 40 percent this year.

To date, 42 knowledge-based companies with a total value of 2.8 quadrillion rials (nearly $66.6 billion) have been listed on the stock exchange and they will soon turn into the biggest businesses in the county," Sattari said.

Potential to produce eco-friendly cars

Car manufacturing has been a monopolized system and breaking it was not that easy, since the beginning, the country's car manufacturing was more of a factory or assembly system so that it has not been moving toward an innovative approach.

But the most important thing in automobile production is a strong research and development department, and we are taking measures to help them produce some auto parts that have been previously imported, yet there would be no reform in the countrys car manufacturing industry.

We are working on smart and electric cars and two active sections are conducting research and development in this field, and we are seriously pursuing it.

Knowledge-based companies have the potential to produce eco-friendly cars, but it takes time to make changes in the industry.

Dealing with environmental issues

Pointing to the activities taken to counter environmental problems, Sattari stated that the firms have so far been developing advanced technologies to address different environmental issues, such as wastewater treatment, water purification, fighting sand and dust storms, alternative cultivation patterns, etc.

Hi-tech tackling environmental issues highly depend on environmental economics which is a sub-category of economics concerned with environmental issues. Particular issues include the costs and benefits of alternative environmental policies to deal with air pollution, water quality, toxic substances, solid waste, and global warming, he suggested.

Environmental economics emphasizes on strong sustainability and rejects the proposition that human-made (physical) capital can substitute for natural capital, he added.

We can never have an environment-based economy if we do not price environmental problems, and the government must enter to tackle any issues, but when there is an economic solution, people will engage and the issue is solved sustainably.

For example, to control a sand and dust storm hotspot, if the government enters, it can solve the problem by mulching for a while, but if businesses enter, an economic aspect will be formed and they can generate revenueandcounterthe environmental problems.

Knowledge-based economy is key to success

Referring to the vision for the next ten years, he said that we are changing the orientation and attitude of universities, and they have changed dramatically in the last five years. The orientation of universities must be solving people's daily problems while earning a significant portion of their revenue from selling technological advances to industries.

We win when the knowledge-based economy becomes the first economy of the country. If this happens, universities will also find their place in society. The difference between a creative and educated person and an ordinary one gets more clear. In a knowledge-based economy, the foundation of change is human, not underground resources, he highlighted.

Sattari went on to emphasize that we are vigorously developing technology centers and expanding all knowledge-based elements, concluding. We have made a serious change in science and technology, but in the next ten years, these changes must be evident in people's daily lives, more importantly, moving towards smart cities.

FB/MG

Read the original here:
Iran is pioneer in biotechnology, ICT, and artificial intelligence in region: VP - Tehran Times

A rating of 24 puts Amarin Corporation plc (AMRN) near the bottom of the Biotechnology industry according to InvestorsObserver. Amarin Corporation plc's score of 24 means it scores higher than 24% of stocks in the industry. Amarin Corporation plc also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Amarin Corporation plc (AMRN) stock is higher by 0.89% while the S&P 500 is down -0.59% as of 10:37 AM on Thursday, Sep 3. AMRN is up $0.05 from the previous closing price of $5.04 on volume of 21,043,437 shares. Over the past year the S&P 500 is up 21.17% while AMRN is down -68.46%. AMRN lost -$0.04 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Amarin Corporation plc (AMRN) Stock.

Go here to read the rest:
Is Amarin Corporation plc (AMRN) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 95 puts Novavax, Inc. (NVAX) near the top of the Biotechnology industry according to InvestorsObserver. Novavax, Inc.'s score of 95 means it scores higher than 95% of stocks in the industry. Novavax, Inc. also received an overall rating of 80, putting it above 80% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Novavax, Inc. (NVAX) stock is up 7.19% while the S&P 500 is down -0.59% as of 10:42 AM on Thursday, Sep 3. NVAX is higher by $7.40 from the previous closing price of $102.90 on volume of 3,449,631 shares. Over the past year the S&P 500 has gained 21.17% while NVAX is higher by 1890.97%. NVAX lost -$2.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Novavax, Inc. (NVAX) Stock.

Originally posted here:
Is Novavax, Inc. (NVAX) a Winner in the Biotechnology Industry? - InvestorsObserver

Introduction: Global Agricultural Biotechnology Market

The global Agricultural Biotechnology market research report is a well synchronized synopsis highlighting some of the most significant, real time research analysis that enable quick and efficient business discretion. The report is a quick reference point to make comply with reader understanding of the volatile market situations that collectively steer enormous growth opportunities in the global Agricultural Biotechnology market.

The report offers a resourceful outline highlighting various facets that encourage remunerative business decisions in the Agricultural Biotechnology market.

The report draws references of growth-oriented business strategies, concomitant competition, business decisions as well as includes references of dynamic segmentation that collectively ensure steady growth in the global Agricultural Biotechnology market.

Top Leading Key Players are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Agricultural Biotechnology Market @https://www.adroitmarketresearch.com/contacts/request-sample/113

The report categorically sheds ample light on multiply market components such as major trends, persistent challenges as well as barriers and threats that significantly restrict growth in the global Agricultural Biotechnology market.

Additionally, to meet with manufacturer needs of opportunity hunting, the report specifically outlines crucial references about major opportunities that steer steady growth and sustainable revenue streams in the global Agricultural Biotechnology market.

COVID-19 Specific Analysis

This up-to-date research report compilation also entices readers to get equipped with ongoing market developments inclusive of unprecedented developments such as COVID-19 outbreak that has crippled businesses and industrial developments in a myriad ways.

The report is structured to highlight effective cues for growth oriented business decisions, allowing manufacturers and stakeholders in the Agricultural Biotechnology market to come up with growth friendly strategies and tactics.

In Agricultural Biotechnology report, participants financial assessments are also included which consists of an evaluation of gross margin, sales volume, cash flow, revenue outcomes, capital investment, and growth rate. That will allow clients to gain intact comprehension of participants financial strengths and position in the worldwide Agricultural Biotechnology industry. Their production capacity, plant locations, Agricultural Biotechnology manufacturing processes, production volume, product specifications, raw material sourcing, distribution networks, and international presence are also analyzed in the report.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

Evaluating Scope: Global Agricultural Biotechnology Market

Vigorous research suggests that the global Agricultural Biotechnology market shall maintain a lucrative growth trail in the coming years, clocking a robust CAGR of xx% through 2020-27.

According to meticulous primary and secondary research endeavors on the part of our in-house research experts, the global Agricultural Biotechnology market is poised to trigger remunerative growth, ticking a total growth of xx million USD in 2020 and is further likely to amplify growth through the forecast tenure, witnessing over xx million USD by 2027.

The report also categorically endeavors to offer requisite understanding about market developments across historic and current perspectives, to make accurate forecast predictions.

Understanding Regional Growth Prognosis: Global Agricultural Biotechnology Market

Following sections of the report on global Agricultural Biotechnology market includes vivid details about region specific developments, also including details about country-specific events that collectively influence optimistic growth.

Additionally, significant details on major market players have also been roped in the report to replicate growth-oriented business discretion.

For Any Query on the Agricultural Biotechnology Market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read the rest here:
Agricultural Biotechnology Market 2020 by Company, Regions, Type and Application, Forecast to 2025 - Owned

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim Statement 31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of 29.6 million compared to 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to 9.6 million from 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from -4.4 million to -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from 20.3 million to 19.1 million in the reporting period. Organically, revenues here increased by 0.4 million or 2.1% from 18.7 million to 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from 2.3 million to 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

See the original post:
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial...

A rating of 85 puts Evogene Ltd (EVGN) near the top of the Biotechnology industry according to InvestorsObserver. Evogene Ltd's score of 85 means it scores higher than 85% of stocks in the industry. Evogene Ltd also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 28 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Evogene Ltd (EVGN) stock is trading at $2.82 as of 11:50 AM on Wednesday, Sep 2, an increase of $0.08, or 2.92% from the previous closing price of $2.74. Volume today is elevated. So far 1,124,639 shares have traded compared to average volume of 361,387 shares. The stock has traded between $2.47 and $2.95 so far today.

Click Here to get the full Stock Score Report on Evogene Ltd (EVGN) Stock.

Read more here:
Is Evogene Ltd (EVGN) The Right Choice in Biotechnology? - InvestorsObserver

The Field of Expertise Human & Biotechnology one of the five research focus areas of Graz University of Technology comprises research activities in the areas of Biomedical Engineer-ing and Biotechnology and includes researchers from the Faculty of Computer Science and Biomedical Engineering and the Faculty of Technical Chemistry, Chemical and Process Engi-neering, Biotechnology. Research results contribute to medicine, environmental technology, industry and agriculture, benefitting society in many aspects.

Graz University of Technology invites applications for an open-topic

Of particular interest is research in Biomedical Engineering (e.g. biomechanics, medical imaging, (clinical) bioinformatics, neural engineering, neuroprosthetics, brain-computer interfaces, computational and experimental electrophysiology, biomedical modelling, biomedical sensor technology, biomaterials) or Molecular Biomedicine (e.g. functional genomics, chemical biology, metabolism research) but also in Industrial Biotechnology (e.g. cell engineering, protein and enzyme engineering, bioprocess engineering, biocatalysis green chemistry, glycoengineering, synthetic biology, computational biotechnology, sensors for process technology) or Environmental Biotechnology (e.g. microbiome research and biotechnology, microbe-plant interactions, food chemistry and human sensors, enzymatic decomposition and modification of (bio-)polymers, use of renewable materials through biotechnological processes).

The professorship will be part of the Field of Human and Biotechnology described athttps://www.tugraz.at/en/research/forschungsschwerpunkte-5-fields-of-expertise/human-biotechnology/overview-human-biotechnology/

Based on the research and teaching focus, the candidate will be assigned to a matching institute and faculty that participate in this Field of Expertise.

Requirements:

Expected Qualifications:

To ensure effective international representation of the research group and its work, excellent spoken and written competence in English is required. Specifically, willingness to teach courses in English is expected. Fluency in German or the willingness to acquire it is also required. The successful candidate is also expected to transfer her/his residence to the area of Graz.

Graz University of Technology aims to increase the proportion of women, in particular in man-agement and academic staff, and therefore qualified female applicants are explicitly encour-aged to apply. Until a balanced ratio of men and women has been achieved at the university, preference will be given to women if applicants are equally qualified.

Graz University of Technology actively promotes diversity and equal opportunities. Applicants are not to be discriminated against in personnel selection procedures on the grounds of gen-der, ethnicity, religion or ideology, age, sexual orientation (Anti-discrimination). People with disabilities who have the relevant qualifications are expressly invited to apply.

Our Offer:

The advertised position is a tenure-track career position for an initial period of 6 years. (pursuant to 99 para. 5 of the Universities Act). After the conclusion of a qualification agreement, the job holder is appointed as an Assistant Professor. After a positive evaluation of the qualification agreement, the position will be turned into a permanent position as Associate Professor. Graz University of Technology provides excellent working conditions in a lively scientific community combined with the outstanding living quality of the Graz area.

The position will be paid according to category B1 of the collective agreement for employees of Austrian universities, stipulating an initial gross salary of EUR 4,309.30 (14 x per year).

Your Application:

Interested applicants are requested to send a detailed application in electronic form, and should quote the position identification number:

at the latest by September 30th, 2020 (date of email) to the Vice Rector of Research via the Research & Technology House of the Graz University of Technology, Horst Bischof, E-Mail: applications.foe@tugraz.at

The interviews for the position are expected to take place in the week from November 16th, 2020. Candidates are asked to be available in this period. For further questions, please contact the head of the Field of Expertise, Gernot Mller-Putz, E-Mail: gernot.mueller@tugraz.at

Vice Rector of Research: Horst BischofPosition identification number: 29/R/PA/93070/20

Go here to see the original:
Tenure-Track Assistant Professorship in the area of Human & - Nature.com

Cabaletta Bio Inc (CABA) is near the top in its industry group according to InvestorsObserver. CABA gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Cabaletta Bio Inc gets a 77 rank in the Biotechnology industry. Biotechnology is number 28 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cabaletta Bio Inc (CABA) stock is trading at $10.33 as of 2:22 PM on Wednesday, Sep 2, an increase of $0.53, or 5.41% from the previous closing price of $9.80. The stock has traded between $9.70 and $10.73 so far today. Volume today is less active than usual. So far 34,817 shares have traded compared to average volume of 87,035 shares.

Click Here to get the full Stock Score Report on Cabaletta Bio Inc (CABA) Stock.

Continue reading here:
Is Cabaletta Bio Inc (CABA) a Winner in the Biotechnology Industry? - InvestorsObserver

Technavio has been monitoring the marine biotechnology market and it is poised to grow by $ 2.5 bn during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005119/en/

Technavio has announced its latest market research report titled Global Marine Biotechnology Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. We offer $1000 worth of FREE customization

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Aker BioMarine AS, BASF SE, CP Kelco, Cyanotech Corp., KD Pharma Group, L'Air Liquide SA, Lonza Group Ltd., Marinomed Biotech AG, PharmaMar SA, and Sea Run Holdings Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The increase in demand for biofuel has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Download a Free Sample Report on COVID-19 Impacts

Marine Biotechnology Market 2020-2024: Segmentation

Marine Biotechnology Market is segmented as below:

Marine Biotechnology Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The marine biotechnology market report covers the following areas:

This study identifies the increasing application of seaweeds as one of the prime reasons driving the marine biotechnology market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Marine Biotechnology Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Story continues

Market Segmentation by Application

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005119/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read the original here:
COVID-19: Marine Biotechnology Market 2020-2024 | The Increase In Demand For Biofuel to boost the Market Growth | Technavio - Yahoo Finance

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Original post:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The global market for media, sera and reagents in biotechnology should reach $5.5 billion by 2023 from $4.1 billion in 2018 at a compound annual growth rate (CAGR) of 6.0% for the period 2018-2023.

Update Scope:

This late 2017 update leverages the structure of the early 2017 report, presenting all the same chapters and major headings, and repeating chapter introductions and other essential content to establish context for the updates. Within this structure, updates are designated with an asterisk (*).

All company profiles from May 2017 are included in the Appendix, along with new companies identified as part of this update.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11818

The scope of the report encompasses the major types of 3D cell culture that have been used, as well as the major applications being developed by industry, academic researchers and their commercialization offices, and government agencies. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed. Other influential factors such as screening strategies for pharmaceuticals have also been included.

Update Includes:

An overview of the global markets and technologies for 3D cell cultures. Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022. Information on 3D technologies, with a focus on representative platforms, including cube, spherical droplet, stacked plate, magnetic bead, and other platforms. Value-chain analysis at the following levels: key innovation or founding intellectual property, prototyping, beta testing, and research collaborations or relationship building. Analysis of the markets dynamics, specifically growth drivers, restraints, and opportunities. Relevant patent analysis, including recent activity and a list of key patents. Profiles of major players in the industry.

Report Summary

This report on 3D cell culture global markets and technology is a comprehensive review of the history of cell culture, current offerings and their adoption dynamics and progress, along with an informed projection of future growth. It contains a sufficient overview of tissue engineering to convey the important touch points, but it focuses on applications of cell and tissue culture as tools for drug discovery and safety testing. This update also reviews applications for development of regenerative medicine.

As background, the report begins in Chapter Three with an overview of tissues and cells, a summary of tissue and cell culture requirements and a brief recap of the history of cell culture, including early learnings from vaccine development.

As additional background and to set the context, Chapter Four provides an overview of the tissue and cell culture systems that have been developed over the past decades across many applications in research and industry. For example, over the past 30 years, 3D cell culture technology and early testing applications have been developed in concert with artificial skin substitutes (therapeutics), as illustrated via representative examples. A number of 3D technologies utilize tissue and cell culture systems calledbioreactors, and many other 3D technologies are often influenced by bioreactor and related developments. A revenue estimate for bioreactors and microcarriers used in 3D solutions is provided.

Key history and technology descriptions are provided in Chapter Five to set the context on the research landscape as additional background for the focus on drug discovery and drug safety testing. In this setting, researchers typically use labware such as T-flasks and Petri dishes with basic microscopes before graduating to microarray technology (e.g., microtiter plates, plate readers) with some going on to use high-content screening (HCS) technology. These tools rely heavily on fluorescence and other detection technologies that can be grouped under the science of cellomics. After an overview of cellomics and microarray technology, subsequent sections detail the ways these technologies are applied to the workings of assays, including cell-based assays, and describe the reagents, cells and other consumablesused in both traditional two-dimensional (2D) and increasingly in 3D cell culture to create new and improved assays. The chapter further describes the key types of assays commonly used in research, details the all-important category of cytotoxicity assays, and positions relevant examples of value-added 3D assay kits and services such as higher throughput (384 and 1536 well) format, kinetic metabolism applications and a case study on a new open innovation platform for 3D. Subsequent chapters detail key3D applications in cancer, toxicology/safety and stem cells.

Chapter Six details 3D cell culture technology types, including gels, scaffolds, bioreactors, hanging droplet platforms for spheroid growth and microchips. These are either sold as raw materials and products bundled onto microplates used by researchers in conjunction with reagents and other consumables to fabricate homebrew assays or as assay kits. This chapter describes the origin and current status on all 3D technologies, including substantial updates on 3D bioprinting and biochips A revenue estimate for 3D technologies and products is provided.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11818

Here is the original post:
Global Markets For Media, Sera And Reagents In Biotechnology Market Future Forecast Assessed On The Basis Of How The Market Is Predicted To Grow -...

Global Polyhydroxyalkanoate (PHA) marketResearch presents a Comprehensive scenario which can be segmented according to producers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Polyhydroxyalkanoate (PHA) business for identifying the growth opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and present Polyhydroxyalkanoate (PHA) industry scenarios and growth facets. Each of the Essential regions coated in Polyhydroxyalkanoate (PHA) report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Polyhydroxyalkanoate (PHA) market share and market prognosis of every region from 2020-2027 are presented within this report. A deep study of Polyhydroxyalkanoate (PHA) marketplace dynamics will help the market aspirants in identifying the business opportunities that will lead to accumulation of earnings. This segment can efficiently determine the Polyhydroxyalkanoate (PHA) hazard and key market driving forces.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.theinsightpartners.com/sample/TIPRE00009497

The Polyhydroxyalkanoate (PHA) report is segmented to provide a clear and precise view of this international Polyhydroxyalkanoate (PHA) market statistics and market quotes. Polyhydroxyalkanoate (PHA) report Information represented in the form of graphs, charts, and statistics will show the Polyhydroxyalkanoate (PHA) growth rate, volume, goal customer analysis. This report presents the significant data to all Polyhydroxyalkanoate (PHA) business aspirants which will facilitate useful business decisions.

Scope of Polyhydroxyalkanoate (PHA) Market:The global Polyhydroxyalkanoate (PHA) market is valued at million US$ in 2019 and will reach million US$ by the end of 2027, growing at a CAGR of during 2020-2027.

This Market Report includesdrivers and restraints of the global Polyhydroxyalkanoate (PHA) market and their impact on each region during the forecast period. The report also comprises the study of current issues with consumers and opportunities. It also includes value chain analysis.

The major vendors covered:

BIO-ON, SHENZHEN ECOMANN BIOTECHNOLOGY CO.,LTD, NEWLIGHT TECHNOLOGIES, INC, POLYFERM CANADA, BIOMER, TIANJIN GREENBIO MATERIALS CO., LTD, DANIMER SCIENTIFIC, BIOSCIENCE, INC, METABOLIX INC, TIANAN BIOLOGIC MATERIALS CO

To Get Discount of Polyhydroxyalkanoate (PHA) Market:https://www.theinsightpartners.com/discount/TIPRE00009497

Regional and Country-level Analysis

Competitive Landscape and Polyhydroxyalkanoate (PHA) Market Share AnalysisPolyhydroxyalkanoate (PHA) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Polyhydroxyalkanoate (PHA) business, the date to enter into the Polyhydroxyalkanoate (PHA) market, Polyhydroxyalkanoate (PHA) product introduction, recent developments, etc.

Some Important Highlights From The Polyhydroxyalkanoate (PHA) Market Report Include:

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPRE00009497

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

For More Information Kindly Contact:Call: +1-646-491-9876Email:[emailprotected]

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

Go here to read the rest:
Polyhydroxyalkanoate (PHA) Market Reviews and Analysis 2020 Along With Study Reports BIO-ON, SHENZHEN ECOMANN BIOTECHNOLOGY CO.,LTD, NEWLIGHT...

Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100

PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the Benzinga Global Small Cap Conference being held virtually October 27-28, 2021.

Event and Registration: Benzinga Global Small Cap ConferencePresentation Date: Thursday, October 28, 2021Presentation Time: 11:55 a.m. ET

Lixte Founder and CEO John S. Kovach, M.D. will deliver a summary of the main features of its lead clinical compound, the PP2A inhibitor LB-100, and an overview of the Companys collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to identify the most promising drug combinations for LB-100 for cancer treatment. The pre-clinical studies are directed by Professor Ren Bernards (NKI), a leader in using genome wide functional genetic techniques to identify effective drug combinations, new drug targets, and mechanisms of resistance to cancer drugs.

Commenting on the collaboration, Dr. Kovach recently stated, We are extremely pleased to have the opportunity to collaborate with Professor Bernards and his excellent group. There are many pre-clinical studies demonstrating the ability of our lead compound, LB-100, an inhibitor of protein phosphatase 2A, to potentiate the activity of different cytotoxic drugs. Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound. A targeted approach to cancer treatment has been a long-standing research goal. Prof. Bernards approach makes it possible to select among a multitude of compounds those most likely to be effective when combined with a second drug and/or in cancers with a particular molecular abnormality. The possibility of identifying which drug in combination with LB-100 and in which type of tumor is most likely to be beneficial is a very exciting prospect.

Story continues

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the on switches because the off switches, especially the master off switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888) 289-5533

View post:
Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28 -...

Ampio Pharmaceuticals Inc (AMPE) is near the top in its industry group according to InvestorsObserver. AMPE gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Ampio Pharmaceuticals Inc gets a 77 rank in the Biotechnology industry. Biotechnology is number 36 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Ampio Pharmaceuticals Inc (AMPE) stock is trading at $1.50 as of 2:05 PM on Tuesday, Jan 19, an increase of $0.15, or 11.11% from the previous closing price of $1.35. The stock has traded between $1.35 and $1.60 so far today. Volume today is low. So far 5,511,356 shares have traded compared to average volume of 10,250,925 shares.

Click Here to get the full Stock Score Report on Ampio Pharmaceuticals Inc (AMPE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Originally posted here:
Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The 166m market-cap company announced a latest loss of 9.7m on 30 September 2020 for its most recent financial year result. The most pressing concern for investors is B.R.A.I.N. Biotechnology Research and Information Network's path to profitability when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

View our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

B.R.A.I.N. Biotechnology Research and Information Network is bordering on breakeven, according to the 6 German Chemicals analysts. They anticipate the company to incur a final loss in 2022, before generating positive profits of 236k in 2023. The company is therefore projected to breakeven around 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 100%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we wont go into details of B.R.A.I.N. Biotechnology Research and Information Network's upcoming projects, however, take into account that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, theres one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 21% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

This article is not intended to be a comprehensive analysis on B.R.A.I.N. Biotechnology Research and Information Network, so if you are interested in understanding the company at a deeper level, take a look at B.R.A.I.N. Biotechnology Research and Information Network's company page on Simply Wall St. We've also compiled a list of key factors you should look at:

PromotedIf you decide to trade B.R.A.I.N. Biotechnology Research and Information Network, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

See the article here:
When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven? - Simply Wall St

U.S. Secretary of Agriculture Sonny Perdue announced a significant step in modernizing regulations of agricultural animals modified or produced by genetic engineering.

The U.S. Department of Agriculture (USDA) will be moving forward with an Advanced Notice of Proposed Rulemaking (ANPR) to solicit public input and feedback on a contemplated regulatory framework that would modernize our system into a scientifically-sound, risk-based, and predictable process that facilitates the development and use of these technologies for U.S. farmers and ranchers under USDA's authorities.

This initiative follows President Donald Trump's Executive Order on agricultural biotechnology that called upon federal agencies to make regulatory improvements to rectify some of the long-standing barriers to innovation for U.S. agriculture.

"Our livestock producers need all the tools in the toolbox to help protect against animal diseases and continue to meet the challenge of feeding everyone now and into the future.

"If we do not put these safe biotechnology advances to work here at home, our competitors in other nations will," said Secretary Perdue.

"Science-based advances in biotechnology have great promise to continue to enhance rural prosperity and improve the quality of life across America's heartland and around the globe.

"With this effort, we are outlining a pragmatic, science-based, and risk-based approach that focuses on potential risk to animal and livestock health, the environment, and food safety in order to provide our farmers and ranchers the tools they need to continue to feed, clothe and fuel the world."

Source: USAgNet

Go here to see the original:
Animal Biotechnology Regulatory Framework Being Transferred to USDA - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Auris Medical Holding Ltd (EARS) is around the middle of the Biotechnology industry according to InvestorsObserver. EARS received an overall rating of 52, which means that it scores higher than 52 percent of all stocks. Auris Medical Holding Ltd also achieved a score of 59 in the Biotechnology industry, putting it above 59 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 52 means the stock is more attractive than 52 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Auris Medical Holding Ltd (EARS) stock is trading at $2.70 as of 9:56 AM on Tuesday, Dec 15, a rise of $0.02, or 0.75% from the previous closing price of $2.68. The stock has traded between $2.62 and $2.87 so far today. Volume today is light. So far 137,427 shares have traded compared to average volume of 12,164,180 shares.

Click Here to get the full Stock Score Report on Auris Medical Holding Ltd (EARS) Stock.

Follow this link:
Where Does Auris Medical Holding Ltd (EARS) Stock Fall in the Biotechnology Field? - InvestorsObserver

Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to 2026Date: 2020-10-12 Author: Ashwin NaphadeCategory: #news

Advanced report on ' Pharmaceutical & Biotechnology Environmental Monitoring market' Added by Market Study Report, LLC, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the ' Pharmaceutical & Biotechnology Environmental Monitoring market'. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

The latest research report on the Pharmaceutical & Biotechnology Environmental Monitoring market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Pharmaceutical & Biotechnology Environmental Monitoring Market at:https://www.marketstudyreport.com/request-a-sample/2947347?utm_source=algosonline.com&utm_medium=Ram

Key pointers from COVID-19 impact analysis:

Important inclusions in the Pharmaceutical & Biotechnology Environmental Monitoring market report:

Ask for Discount on Pharmaceutical & Biotechnology Environmental Monitoring Market Report at:https://www.marketstudyreport.com/check-for-discount/2947347?utm_source=algosonline.com&utm_medium=Ram

Regional scope:

TOC of Pharmaceutical & Biotechnology Environmental Monitoring Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-pharmaceutical-biotechnology-environmental-monitoring-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

2. Global Metabolomics Reagents Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-metabolomics-reagents-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/air-sampling-pumps-market-size-analysis-share-growth-trends-top-key-players-and-regional-forecast-2025-2020-10-09

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Here is the original post:
Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to...

The 58 rating InvestorsObserver gives to Translate Bio Inc (TBIO) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 66 percent of stocks in the Biotechnology industry, TBIOs 58 overall rating means the stock scores better than 58 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 58 would rank higher than 58 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Translate Bio Inc (TBIO) stock is up 2.71% while the S&P 500 has fallen -0.88% as of 9:51 AM on Thursday, Oct 15. TBIO has risen $0.40 from the previous closing price of $14.75 on volume of 97,812 shares. Over the past year the S&P 500 has gained 15.66% while TBIO has risen 77.40%. TBIO lost -$1.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Translate Bio Inc (TBIO) Stock.

Go here to read the rest:
Is Translate Bio Inc (TBIO) the Top Pick in the Biotechnology Industry? - InvestorsObserver